HomeRydapt

Rydapt

Also known as: Rydapt

Kinase InhibitorReceptor Tyrosine Kinase Inhibitors

Route: Oral

Check Rydapt Interactions →
29 interactions on record

Rydapt has 29 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Enzalutamide, Mitotane. Patients taking Rydapt should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
29
Major
6
Moderate
23

Major (6)

  • Rydapt + CarbamazepineStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
  • Rydapt + EnzalutamideStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
  • Rydapt + MitotaneStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
  • Rydapt + PhenytoinStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
  • Rydapt + RifampinStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration.
  • Rydapt + St. John'S WortStrong CYP3A4 inducer that decreases midostaurin concentrations and may reduce efficacy. Avoid coadministration. Inducti

Moderate (23)

  • Rydapt + BoceprevirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + ClarithromycinStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + CobicistatStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + ConivaptanStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + DasabuvirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + DiltiazemStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + ElvitegravirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + Grapefruit JuiceStrong CYP3A4 inhibitor (with certain preparations) that may increase midostaurin concentrations. Effect varies by brand
  • Rydapt + IdelalisibStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + IndinavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + ItraconazoleStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + KetoconazoleStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + LopinavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + NefazodoneStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + NelfinavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + OmbitasvirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + ParitaprevirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + PosaconazoleStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + RitonavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + SaquinavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + TipranavirStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + TroleandomycinStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse
  • Rydapt + VoriconazoleStrong CYP3A4 inhibitor that may increase midostaurin concentrations and risk of toxicity. Monitor for increased adverse

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.